Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Mar;51(3):424–429. doi: 10.1136/ard.51.3.424

Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

H A Capell 1, M Brzeski 1
PMCID: PMC1004681  PMID: 1575601

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ash G., Baker R., Rajapakse C., Swinson D. R. Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol. 1986 Aug;25(3):285–287. doi: 10.1093/rheumatology/25.3.285. [DOI] [PubMed] [Google Scholar]
  2. Bax D. E., Amos R. S. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis. 1986 Feb;45(2):139–140. doi: 10.1136/ard.45.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belch J. J., Madhok R., McArdle B., McLaughlin K., Kluft C., Forbes C. D., Sturrock R. D. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Q J Med. 1986 Jan;58(225):19–27. [PubMed] [Google Scholar]
  4. Borg G., Allander E., Lund B., Berg E., Brodin U., Pettersson H., Trang L. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol. 1988 Dec;15(12):1747–1754. [PubMed] [Google Scholar]
  5. Breedveld F. C., Dijkmans B. A., Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol. 1990 Jan;17(1):43–46. [PubMed] [Google Scholar]
  6. Brower A. C. Use of the radiograph to measure the course of rheumatoid arthritis. The gold standard versus fool's gold. Arthritis Rheum. 1990 Mar;33(3):316–324. doi: 10.1002/art.1780330303. [DOI] [PubMed] [Google Scholar]
  7. Brzeski M., Madhok R., Hunter J. A., Capell H. A. Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis. Ann Rheum Dis. 1990 May;49(5):293–295. doi: 10.1136/ard.49.5.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Capell H. A., Hunter J. A., Rennie J. A., Murdoch R. M. Levamisole - a possible alternative to gold and penicillamine in the longterm treatment of rheumatoid arthritis? J Rheumatol. 1981 Sep-Oct;8(5):730–740. [PubMed] [Google Scholar]
  9. Capell H. A., Marabani M., Madhok R., Torley H., Hunter J. A. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. Q J Med. 1990 Apr;75(276):335–344. [PubMed] [Google Scholar]
  10. Carette S., Calin A., McCafferty J. P., Wallin B. A. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum. 1989 Feb;32(2):158–165. doi: 10.1002/anr.1780320208. [DOI] [PubMed] [Google Scholar]
  11. Caruso I., Montrone F., Fumagalli M., Patrono C., Santandrea S., Gandini M. C. Rheumatoid knee synovitis successfully treated with intra-articular rifamycin SV. Ann Rheum Dis. 1982 Jun;41(3):232–236. doi: 10.1136/ard.41.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dahl S. L., Coleman M. L., Williams H. J., Altz-Smith M., Kay D. R., Paulus H. E., Weinstein A., Kaplan S. Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate. Arthritis Rheum. 1985 Nov;28(11):1211–1218. doi: 10.1002/art.1780281104. [DOI] [PubMed] [Google Scholar]
  13. Dennison W. B., Loeser R. F., Turner R. A., Johnson J. A., Wells H. B. A double blind placebo controlled trial of low dose clotrimazole in rheumatoid arthritis. J Rheumatol. 1990 Aug;17(8):1003–1007. [PubMed] [Google Scholar]
  14. Egsmose C., Lund B., Andersen R. B. Timegadine: more than a non-steroidal for the treatment of rheumatoid arthritis. A controlled, double-blind study. Scand J Rheumatol. 1988;17(2):103–111. doi: 10.3109/03009748809098769. [DOI] [PubMed] [Google Scholar]
  15. Felson D. T., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. doi: 10.1002/art.1780331001. [DOI] [PubMed] [Google Scholar]
  16. Furst D. E. Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs fail. Semin Arthritis Rheum. 1990 Oct;20(2):69–75. doi: 10.1016/0049-0172(90)90019-c. [DOI] [PubMed] [Google Scholar]
  17. Gabriel S. E., Conn D. L., Luthra H. Rifampin therapy in rheumatoid arthritis. J Rheumatol. 1990 Feb;17(2):163–166. [PubMed] [Google Scholar]
  18. Grimaldi M. G. Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response. Br J Clin Pharmacol. 1981 Oct;12(4):579–581. doi: 10.1111/j.1365-2125.1981.tb01268.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hannan M. T., Felson D. T., Anderson J. J., Naimark A., Kannel W. B. Estrogen use and radiographic osteoarthritis of the knee in women. The Framingham Osteoarthritis Study. Arthritis Rheum. 1990 Apr;33(4):525–532. doi: 10.1002/art.1780330410. [DOI] [PubMed] [Google Scholar]
  20. Harkness J. A., Griffin A. J., Heinrich I., Gibson T., Grahame R. A double-blind comparative study of metronidazole and placebo in rheumatoid arthritis. Rheumatol Rehabil. 1982 Nov;21(4):231–234. doi: 10.1093/rheumatology/21.4.231. [DOI] [PubMed] [Google Scholar]
  21. Harris E. D., Jr Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990 May 3;322(18):1277–1289. doi: 10.1056/NEJM199005033221805. [DOI] [PubMed] [Google Scholar]
  22. Iannuzzi L., Dawson N., Zein N., Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983 Oct 27;309(17):1023–1028. doi: 10.1056/NEJM198310273091704. [DOI] [PubMed] [Google Scholar]
  23. Klippel J. H. Winning the battle, losing the war? Another editorial about rheumatoid arthritis. J Rheumatol. 1990 Sep;17(9):1118–1122. [PubMed] [Google Scholar]
  24. Kremer J. M., Lee J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986 Jul;29(7):822–831. doi: 10.1002/art.1780290702. [DOI] [PubMed] [Google Scholar]
  25. Larkin J. G., Capell H. A., Sturrock R. D. Seatone in rheumatoid arthritis: a six-month placebo-controlled study. Ann Rheum Dis. 1985 Mar;44(3):199–201. doi: 10.1136/ard.44.3.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Madhok R., Pullar T., Capell H. A., Dawood F., Sturrock R. D., Dick H. M. Chrysotherapy and thrombocytopenia. Ann Rheum Dis. 1985 Sep;44(9):589–591. doi: 10.1136/ard.44.9.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Malaise M. G., Hauwaert C., Franchimont P., Danneskiold-Samsoe B., Bach-Andersen R., Gross D., Gerber H., Gerschpacher H., Stocker H., Bolla K. Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Lancet. 1985 Apr 13;1(8433):832–836. doi: 10.1016/s0140-6736(85)92205-6. [DOI] [PubMed] [Google Scholar]
  28. Martin M. F., Surrall K. E., McKenna F., Dixon J. S., Bird H. A., Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325–1328. doi: 10.1016/s0140-6736(84)91821-x. [DOI] [PubMed] [Google Scholar]
  29. McCarty D. J. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol. 1990 Sep;17(9):1115–1118. [PubMed] [Google Scholar]
  30. McConkey B. Sulphasalazine and ankylosing spondylitis. Br J Rheumatol. 1990 Feb;29(1):2–3. [PubMed] [Google Scholar]
  31. Moran M., Mozes M. F., Maddux M. S., Veremis S., Bartkus C., Ketel B., Pollak R., Wallemark C., Jonasson O. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 1990 Apr 26;322(17):1183–1188. doi: 10.1056/NEJM199004263221703. [DOI] [PubMed] [Google Scholar]
  32. Paulus H. E. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):113–120. doi: 10.1002/art.1780330116. [DOI] [PubMed] [Google Scholar]
  33. Pullar T., Capell H. A. A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis. 1985 Feb;44(2):134–140. doi: 10.1136/ard.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pullar T., Capell H. A. Selection of suitable patients for second-line therapy in rheumatoid arthritis. Br J Rheumatol. 1986 Aug;25(3):276–281. doi: 10.1093/rheumatology/25.3.276. [DOI] [PubMed] [Google Scholar]
  35. Pullar T., Hunter J. A., Capell H. A. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis. 1985 Dec;44(12):831–837. doi: 10.1136/ard.44.12.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pullar T., Hunter J. A., Capell H. A. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis. 1987 May;46(5):398–402. doi: 10.1136/ard.46.5.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol. 1985 Aug;24(3):269–276. doi: 10.1093/rheumatology/24.3.269. [DOI] [PubMed] [Google Scholar]
  39. Pullar T., Peaker S., Martin M. F., Bird H. A., Feely M. P. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol. 1988 Oct;27(5):381–384. doi: 10.1093/rheumatology/27.5.381. [DOI] [PubMed] [Google Scholar]
  40. Rantapä Dahlqvist S., Mjörndal T. Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine. Scand J Rheumatol. 1987;16(4):235–239. doi: 10.3109/03009748709102923. [DOI] [PubMed] [Google Scholar]
  41. Reidenberg M. M., Case D. B., Drayer D. E., Reis S., Lorenzo B. Development of antinuclear antibody in patients treated with high doses of captopril. Arthritis Rheum. 1984 May;27(5):579–581. doi: 10.1002/art.1780270516. [DOI] [PubMed] [Google Scholar]
  42. Richards I. M., Fraser S. M., Hunter J. A., Capell H. A. Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis. Ann Rheum Dis. 1987 Sep;46(9):667–669. doi: 10.1136/ard.46.9.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Scott D. L., Dawes P. T., Fowler P. D., Grindulis K. A., Shadforth M., Bacon P. A. Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med. 1985 Jan;54(213):49–59. [PubMed] [Google Scholar]
  44. Scott D. L., Dawes P. T., Tunn E., Fowler P. D., Shadforth M. F., Fisher J., Clarke S., Collins M., Jones P., Popert A. J. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol. 1989 Apr;28(2):128–133. doi: 10.1093/rheumatology/28.2.128. [DOI] [PubMed] [Google Scholar]
  45. Situnayake R. D., Grindulis K. A., McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987 Mar;46(3):177–183. doi: 10.1136/ard.46.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Steven M. M., Hunter J. A., Murdoch R. M., Capell H. A. Does the order of second-line treatment in rheumatoid arthritis matter? Br Med J (Clin Res Ed) 1982 Jan 9;284(6309):79–81. doi: 10.1136/bmj.284.6309.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Teh L. G., Madhok R., Capell H. A. Does the addition of ketotifen to non-steroidal anti-inflammatory drugs confer any additional benefit in rheumatoid arthritis? Br J Clin Pharmacol. 1984 Feb;17(2):157–159. doi: 10.1111/j.1365-2125.1984.tb02330.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tugwell P., Bombardier C., Gent M., Bennett K. J., Bensen W. G., Carette S., Chalmers A., Esdaile J. M., Klinkhoff A. V., Kraag G. R. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990 May 5;335(8697):1051–1055. doi: 10.1016/0140-6736(90)92630-z. [DOI] [PubMed] [Google Scholar]
  49. Weinblatt M. E., Kaplan H., Germain B. F., Merriman R. C., Solomon S. D., Wall B., Anderson L., Block S., Irby R., Wolfe F. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum. 1990 Mar;33(3):330–338. doi: 10.1002/art.1780330305. [DOI] [PubMed] [Google Scholar]
  50. Wijnands M. J., van Riel P. L., Gribnau F. W., van de Putte L. B. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Semin Arthritis Rheum. 1990 Jun;19(6):337–352. doi: 10.1016/0049-0172(90)90071-m. [DOI] [PubMed] [Google Scholar]
  51. Williams H. J., Ward J. R., Dahl S. L., Clegg D. O., Willkens R. F., Oglesby T., Weisman M. H., Schlegel S., Michaels R. M., Luggen M. E. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum. 1988 Jun;31(6):702–713. doi: 10.1002/art.1780310602. [DOI] [PubMed] [Google Scholar]
  52. Willkens R. F., Leonard P. A., Clegg D. O., Tolman K. G., Ward J. R., Marks C. R., Greene M. L., Roth G. J., Jackson C. G., Cannon G. W. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis. 1990 Aug;49(8):591–593. doi: 10.1136/ard.49.8.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Willkens R. F. Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis. Semin Arthritis Rheum. 1990 Oct;20(2):76–80. doi: 10.1016/0049-0172(90)90020-g. [DOI] [PubMed] [Google Scholar]
  54. Wilske K. R., Healey L. A. Remodeling the pyramid--a concept whose time has come. J Rheumatol. 1989 May;16(5):565–567. [PubMed] [Google Scholar]
  55. Wolfe F., Hawley D. J., Cathey M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990 Aug;17(8):994–1002. [PubMed] [Google Scholar]
  56. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  57. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., Gribnau F. W., vad de Putte L. B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989 May 13;1(8646):1036–1038. doi: 10.1016/s0140-6736(89)92442-2. [DOI] [PubMed] [Google Scholar]
  58. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., van de Putte L. B. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 1990 Mar 3;335(8688):539–539. doi: 10.1016/0140-6736(90)90771-v. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES